Quantcast

Latest Dana-Farber Cancer Institute Stories

2012-04-05 09:21:12

A paradigm shift in anti-tumor efficacy and safety in cancer patients A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug...

2012-03-29 09:07:59

Dana-Farber president: Encouraging news, but improvements are still needed A report from the nation's leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2004 and 2008. The findings come from the latest Annual Report to the Nation on the Status of Cancer. The report also finds that the overall rate of new cancer diagnoses for men and women combined decreased an average of less than one percent per...

2012-03-29 02:25:23

First volume of the Cancer Cell Line Encyclopedia made public The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents. Now an academic-industry collaboration is releasing the first results from a new and freely available resource that marries deeply detailed cancer...

2012-03-27 05:17:46

(Ivanhoe Newswire) — Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients...

2012-03-22 22:34:14

Marker identifies tumors unable to repair DNA damage by platinum agents Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies. The marker, found on chromosomes within the cancer cells, could lead to a test for identifying patients whose cancers could be effectively treated...

2012-03-22 22:32:59

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients with triple-negative breast...

2012-03-15 12:00:00

South Korea´s largest hospital to offer dynamic digital publication for the international medical traveler Chapel Hill, NC (PRWEB) March 15, 2012 Patients Beyond Borders, the best-selling consumer reference guide on medical tourism, is pleased to announce the official launch of FOCUS ON: Asan Medical Center, profiling South Korea´s largest nonprofit hospital. FOCUS ON: Asan Medical Center will feature the medical center´s world-class facilities, highlight its pioneering...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related